The Doctor's Farmacy With Mark Hyman, M.d.

Like most things in life, when it comes to optimizing metabolic health, a nuanced perspective can help. Rather than viewing it as a black-and-white issue, we can take into consideration the big-picture social context we’re facing that encourages ultra-processed foods, obesity, and lifelong medication as well as the micro-level of what people are experiencing as individuals and understanding how to help them when all else fails.  Today I’m thrilled to sit down with Dr. Tyna Moore and Calley Means for a grounded discussion that explores both sides of the spectrum, and everything in between.  In this episode, we discuss: The controversial discussion of GLP-1 agonists like Ozempic, weighing the pros and cons of these new drugs in treating obesity and metabolic crises (3:34) Challenging the notion of treating obesity with drugs like Ozempic (10:35) An unsettling revelation about the push for using Ozempic in children (12:04) Digging deeper into GLP-1 research and some of the benefits (32:51) Why are children